A Phase II Correlative Clinical Trial of MLN8237, a Selective Aurora Kinase A (AURKA) Inhibitor, in Patients With Unresectable Stage III or Stage IV Melanoma Disease.

Trial Profile

A Phase II Correlative Clinical Trial of MLN8237, a Selective Aurora Kinase A (AURKA) Inhibitor, in Patients With Unresectable Stage III or Stage IV Melanoma Disease.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2016

At a glance

  • Drugs Alisertib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Aug 2015 Planned End Date changed from 1 Oct 2019 to 1 Mar 2016 as reported by ClinicalTrials.gov.
    • 28 Aug 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
    • 15 Mar 2012 New source identified and integrated (Vanderbilt-Ingram Cancer Center; VICCMEL1036).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top